Cure My Disease

Don't miss your cure!

 Log in / Sign up

New web tool aims to keep men with Low-Risk prostate cancer on track without unnecessary treatment

NCT ID NCT05764005

Knowledge-focused Sponsor: University of Michigan Rogel Cancer Center Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed This study
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This pilot study tested a web-based tool called MAP (Management of Active surveillance in Prostate Cancer) in 39 men aged 55+ with low-risk prostate cancer who were already on active surveillance. The tool provides education, helps coordinate care with primary care doctors, and offers self-management tips for cancer-related anxiety. The goal was to see if the tool is feasible and acceptable to patients and providers, with results to inform a larger future study.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
web-based tool (MAP - Management of Active surveillance in Prostate Cancer)
What this could lead to
If successful, this could lead to a larger study that improves how men with low-risk prostate cancer are monitored, reducing unnecessary treatments.
What could go wrong
This is a small pilot study with only 39 participants, so results may not apply to everyone. The tool is behavioral, not a treatment, so it won't cure or control the cancer directly.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

39 people

The number who actually took part.

Started

Nov 2022

Finished

Mar 2024

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

55 years and older

Sex

Male participants only

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Patient Inclusion Criteria: * 55 years old or older * Men diagnosed with low-risk prostate cancer currently on active surveillance * Men who identify having a primary care provider * Access and ability to use the Internet Patient Exclusion Criteria: * Men who are unable to read and/or speak English * Men with impaired decision-making capacity (such as with a diagnosis of dementia or memory loss) PCP Inclusion Criteria: * Identified by patient on baseline survey as their PCP Urologist and Clinic Staff Inclusion Criteria: * Clinicians or staff at a participating urology clinic, including but not limited to MDs, APPs, and nurses

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Prostate cancer are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

prostate cancer

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Prostate cancer

Contacts and locations

Locations

  • University of Michigan Rogel Cancer Center

    Ann Arbor, Michigan, 48109, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.